Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Administration of CBG000592 (riboflavin/vitamin B2) in patients with acute ischemic stroke to
know if it causes a reduction of glutamate-mediated excitotoxicity.